Rachel Rennard
Senior Vice President, Research Stereo Biotherapeutics
Seminars
Thursday 25th June 2026
Building Multi‑Specific T‑Cell Engagers for Heterogeneous, Hard‑to‑Treat Tumors
12:00 pm
- A purpose‑built approach addresses the limiting challenges of narrow therapeutic windows and target heterogeneity by extending T‑cell engager success to pMHC targets
- Trackers, small soluble TCR‑derived binding elements, leverage the natural pMHC–TCR interaction to drive precise tumor cell killing while maintaining antibody‑like developability
- The Broadcast platform identifies optimal target pairs, discovers and optimizes novel Trackers with drug‑like properties, and designs multi‑specific formats that expand tumor coverage and increase the number of patients with potential to benefit
